Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
PaperCitations, authors & open-access status
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 175 citations, 2021 year and gold oa status.
175
Citations
2021
Year
gold
OA Status